Multicenter Phase 2 Study of Concurrent Chemoradiation Therapy Plus Peri-Irradiation Chemotherapy for Inoperable Nonmetastatic Gastric Cancer.

T. Chen,Yingbin Liu,Z. Guoqi,Yi Xu,Xia He,Xiaodong Li,Hui Chen,S. Yao

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.085

IF: 8.013

2016-01-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Surgery is the optimal treatment for localized gastric cancer, but is impossible in about 30% of cases. This multicenter phase II study assessed the efficacy and feasibility of concurrent chemoradiotherapy (CCRT) plus pre- and post-radiation chemotherapy for inoperable gastric cancer. Patients with histologically confirmed non-metastatic (M0) gastric cancer that was medically inoperable were eligible for this study. Other inclusion criteria were that patients should have uni- or bi-dimensionally measurable disease and Zubrod performance status of 0–2. Patients received up to two 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1–3, and a continuous infusion of 5-FU 750 mg/m2 on days 1–5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of intensity-modulated radiation therapy plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks. The gross tumor volume (GTV) was defined as the pre-chemotherapy primary tumor volume and clinically positive lymph nodes. The clinical tumor volume (CTV) included GTV with a 4-5cm margin, together with draining lymph nodes. The PTV (CTV + 0.5 cm margin) was to receive a total dose of 45 Gy in 25 fractions at 1.8 Gy per fraction delivered once daily for 5 weeks, followed by a boost of 5.4 Gy in 3 fractions at 1.8 Gy to BGTV(GTV + 2-3 cm margin) up to a total dose of 50.4 Gy. The primary end point of this study was the clinical complete response (cCR) rate, defined as the absence of tumor cells in the endoscopic biopsy and the complete disappearance of all measurable disease on imaging studies. The sample size was calculated using a Simon’s 2-stage optimal design. assuming alpha and beta errors of 5% and 10%, respectively, with the assumption that a cCR rate of 30% or greater would be sufficiently promising to justify further investigation of this regimen. A sample size of 35 was required. Thirty-six patients were evaluable (median age, 61 years). Twenty-one patients with comorbid conditions were unsuitable for surgery, 8 patients had unresectable disease, and 7 patients refused surgery. Stage T1-2, 10; T3, 21; and T4, 5. Stage N0, 10; N1, 15; N2, 9; N3, 2 (AJCC, 2010). Twenty-two patients (67%) had a tumor sized ≤5 cm. The cCR rate was 36% (95% confidence interval [CI], 19–53%) and the overall response rate was 83% (95% CI, 75–97%). Patients with a tumor sized ≤5 cm achieved a higher cCR rate than those with tumor sized >5 cm (54% vs 0, P = 0.002). The median survival time and 3-year survival rate were 25.8 months (95% CI = 7.1–44.5 months) and 42% (95% CI = 23–59%), respectively. Achieving a cCR was associated with significantly better overall survival (P = 0.004). The most common grade 3 or greater toxicity (NCI-CTC, 3.0) during pre- and post-radiation chemotherapy was neutropenia (22%). Common grade 3/4 toxicities during CCRT were nausea (31%), vomiting (26%), and stomatitis (23%). This regimen is tolerable and shows promising efficacy in inoperable gastric cancer.